vs
Side-by-side financial comparison of LANDSTAR SYSTEM INC (LSTR) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
LANDSTAR SYSTEM INC is the larger business by last-quarter revenue ($1.2B vs $699.9M, roughly 1.7× QuidelOrtho Corp). LANDSTAR SYSTEM INC runs the higher net margin — 3.4% vs -104.7%, a 108.1% gap on every dollar of revenue. On growth, LANDSTAR SYSTEM INC posted the faster year-over-year revenue change (1.6% vs -3.7%). Over the past eight quarters, LANDSTAR SYSTEM INC's revenue compounded faster (-2.2% CAGR vs -2.9%).
Landstar System, Inc. is an American transportation services company specializing in logistics and, more specifically, third-party logistics. Landstar utilizes an extensive network of over 8,800 independent owner-operators, referred to internally as business capacity owners (BCOs), over 1,000 independent freight agents, and over 70,000 vetted carriers. Landstar provides services principally throughout the United States and to a lesser extent in Canada and between the U.S. and Canada, Mexico, ...
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
LSTR vs QDEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $699.9M |
| Net Profit | $39.4M | $-733.0M |
| Gross Margin | 9.6% | — |
| Operating Margin | 4.5% | -100.7% |
| Net Margin | 3.4% | -104.7% |
| Revenue YoY | 1.6% | -3.7% |
| Net Profit YoY | 32.3% | -3583.4% |
| EPS (diluted) | $1.16 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | $699.9M | ||
| Q2 25 | $1.2B | $613.9M | ||
| Q1 25 | $1.2B | $692.8M | ||
| Q4 24 | $1.2B | $707.8M | ||
| Q3 24 | $1.2B | $727.1M | ||
| Q2 24 | $1.2B | $637.0M |
| Q1 26 | $39.4M | — | ||
| Q4 25 | $23.9M | — | ||
| Q3 25 | $19.4M | $-733.0M | ||
| Q2 25 | $41.9M | $-255.4M | ||
| Q1 25 | $29.8M | $-12.7M | ||
| Q4 24 | $46.2M | $-178.4M | ||
| Q3 24 | $50.0M | $-19.9M | ||
| Q2 24 | $52.6M | $-147.7M |
| Q1 26 | 9.6% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | 4.5% | — | ||
| Q4 25 | 2.5% | — | ||
| Q3 25 | 2.2% | -100.7% | ||
| Q2 25 | 4.6% | -29.4% | ||
| Q1 25 | 3.4% | 4.7% | ||
| Q4 24 | 4.8% | -14.2% | ||
| Q3 24 | 5.2% | 2.1% | ||
| Q2 24 | 5.6% | -18.4% |
| Q1 26 | 3.4% | — | ||
| Q4 25 | 2.0% | — | ||
| Q3 25 | 1.6% | -104.7% | ||
| Q2 25 | 3.5% | -41.6% | ||
| Q1 25 | 2.6% | -1.8% | ||
| Q4 24 | 3.8% | -25.2% | ||
| Q3 24 | 4.1% | -2.7% | ||
| Q2 24 | 4.3% | -23.2% |
| Q1 26 | $1.16 | — | ||
| Q4 25 | $0.70 | — | ||
| Q3 25 | $0.56 | $-10.78 | ||
| Q2 25 | $1.20 | $-3.77 | ||
| Q1 25 | $0.85 | $-0.19 | ||
| Q4 24 | $1.30 | $-2.54 | ||
| Q3 24 | $1.41 | $-0.30 | ||
| Q2 24 | $1.48 | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $411.0M | $98.1M |
| Total DebtLower is stronger | $26.1M | $2.5B |
| Stockholders' EquityBook value | $799.0M | $2.0B |
| Total Assets | $1.6B | $5.7B |
| Debt / EquityLower = less leverage | 0.03× | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $411.0M | — | ||
| Q4 25 | $452.2M | — | ||
| Q3 25 | $434.4M | $98.1M | ||
| Q2 25 | $426.2M | $151.7M | ||
| Q1 25 | $473.4M | $127.1M | ||
| Q4 24 | $566.6M | $98.3M | ||
| Q3 24 | $531.3M | $143.7M | ||
| Q2 24 | $504.0M | $107.0M |
| Q1 26 | $26.1M | — | ||
| Q4 25 | $0 | — | ||
| Q3 25 | $0 | $2.5B | ||
| Q2 25 | $0 | $2.1B | ||
| Q1 25 | $0 | $2.1B | ||
| Q4 24 | $0 | $2.1B | ||
| Q3 24 | $0 | $2.2B | ||
| Q2 24 | $0 | $2.2B |
| Q1 26 | $799.0M | — | ||
| Q4 25 | $795.7M | — | ||
| Q3 25 | $888.7M | $2.0B | ||
| Q2 25 | $921.8M | $2.8B | ||
| Q1 25 | $930.8M | $3.0B | ||
| Q4 24 | $972.4M | $3.0B | ||
| Q3 24 | $1.0B | $3.2B | ||
| Q2 24 | $1.0B | $3.2B |
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.7B | $5.7B | ||
| Q2 25 | $1.7B | $6.4B | ||
| Q1 25 | $1.7B | $6.5B | ||
| Q4 24 | $1.8B | $6.4B | ||
| Q3 24 | $1.8B | $6.8B | ||
| Q2 24 | $1.8B | $6.7B |
| Q1 26 | 0.03× | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | 1.23× | ||
| Q2 25 | 0.00× | 0.74× | ||
| Q1 25 | 0.00× | 0.70× | ||
| Q4 24 | 0.00× | 0.72× | ||
| Q3 24 | 0.00× | 0.68× | ||
| Q2 24 | 0.00× | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-45.5M |
| Free Cash FlowOCF − Capex | — | $-94.7M |
| FCF MarginFCF / Revenue | — | -13.5% |
| Capex IntensityCapex / Revenue | — | 7.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $72.7M | — | ||
| Q3 25 | $89.3M | $-45.5M | ||
| Q2 25 | $7.1M | $-46.8M | ||
| Q1 25 | $55.7M | $65.6M | ||
| Q4 24 | $61.1M | $63.7M | ||
| Q3 24 | $83.1M | $117.9M | ||
| Q2 24 | $48.1M | $-97.9M |
| Q1 26 | — | — | ||
| Q4 25 | $70.5M | — | ||
| Q3 25 | $86.0M | $-94.7M | ||
| Q2 25 | $4.7M | $-84.3M | ||
| Q1 25 | $53.8M | $9.4M | ||
| Q4 24 | $54.4M | $16.5M | ||
| Q3 24 | $75.6M | $71.4M | ||
| Q2 24 | $40.6M | $-133.2M |
| Q1 26 | — | — | ||
| Q4 25 | 6.0% | — | ||
| Q3 25 | 7.1% | -13.5% | ||
| Q2 25 | 0.4% | -13.7% | ||
| Q1 25 | 4.7% | 1.4% | ||
| Q4 24 | 4.5% | 2.3% | ||
| Q3 24 | 6.2% | 9.8% | ||
| Q2 24 | 3.3% | -20.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.3% | 7.0% | ||
| Q2 25 | 0.2% | 6.1% | ||
| Q1 25 | 0.2% | 8.1% | ||
| Q4 24 | 0.6% | 6.7% | ||
| Q3 24 | 0.6% | 6.4% | ||
| Q2 24 | 0.6% | 5.5% |
| Q1 26 | — | — | ||
| Q4 25 | 3.04× | — | ||
| Q3 25 | 4.61× | — | ||
| Q2 25 | 0.17× | — | ||
| Q1 25 | 1.87× | — | ||
| Q4 24 | 1.32× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 0.91× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LSTR
Segment breakdown not available.
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
